Maxcyte (MXCT) Total Non-Current Liabilities (2020 - 2026)

Maxcyte (MXCT) has reported Total Non-Current Liabilities for 7 consecutive years, with $25.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 10.98% year-over-year to $25.6 million in Q2 2026; TTM through Jun 2026 was $25.6 million, a 10.98% decrease from a year earlier, with the FY2025 full-year figure at $30.8 million, down 6.65% from the prior year.
• Total Non-Current Liabilities was $25.6 million for Q2 2026 at Maxcyte, down from $26.3 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $35.8 million in Q4 2023 and troughed at $25.6 million in Q2 2026.
• A 5-year average of $30.9 million and a median of $31.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities surged 144.74% in 2022 and slipped 13.06% in 2026, its largest moves.
• Over 5 years, Total Non-Current Liabilities stood at $31.4 million in 2022, then gained by 14.22% to $35.8 million in 2023, then decreased by 8.04% to $32.9 million in 2024, then decreased by 6.65% to $30.8 million in 2025, then fell by 16.7% to $25.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $25.6 million (Q2 2026), $26.3 million (Q1 2026), and $30.8 million (Q4 2025), per Business Quant data.